Exeltis USA Dermatology, LLC
Exeltis is a global healthcare company dedicated to developing innovative treatments and addressing unmet medical needs. With nearly 4,000 professionals across over 40 countries, Exeltis operates its own manufacturing network with advanced technology in plants located in Turkey, Guatemala, Paraguay, India, and Indonesia. The company emphasizes quality, innovation, and patient-centric solutions, with a strong presence in pharmaceutical and nutritional specialties. Exeltis is committed to environmental protection, health and safety, and social responsibility, actively participating in initiatives like Mundo Sano to combat neglected diseases such as Chagas. The company maintains a comprehensive portfolio of products and services, and collaborates with global research centers to improve health outcomes worldwide.
Industries
Nr. of Employees
Very Large (1000+)
Exeltis USA Dermatology, LLC
Calle Manuel Pombo Angulo, 28 3ª planta 28050 Madrid, Spain
Patents
Products
Pharmaceutical and nutritional specialties portfolio (~300 SKUs)
A broad portfolio of pharmaceutical and nutritional specialty products across multiple therapeutic areas and formats; portfolio size reported as approximately 300 specialties.
Pharmaceutical and nutritional specialties portfolio (~300 SKUs)
A broad portfolio of pharmaceutical and nutritional specialty products across multiple therapeutic areas and formats; portfolio size reported as approximately 300 specialties.
Services
On-site manufacturing services for a broad set of dosage forms (tablets, capsules, liquids, creams, gels, foams, suppositories, ovules, inhalation products, sachets and vials).
Manufacturing and technology transfer support for biologic active ingredients and vaccine production, including coordination of fill–finish in partner sites.
Provision of in-house research capacity and partnership-based research with external institutes to support drug development and evidence generation.
Mentorship, business development, internationalisation and investor-preparation services for early-stage health startups.
Design and deployment of patient engagement initiatives to integrate patient perspectives into product development and communication.
Regional commercial offices and local contact points across 40+ countries to support market access, distribution and customer service.
On-site manufacturing services for a broad set of dosage forms (tablets, capsules, liquids, creams, gels, foams, suppositories, ovules, inhalation products, sachets and vials).
Manufacturing and technology transfer support for biologic active ingredients and vaccine production, including coordination of fill–finish in partner sites.
Provision of in-house research capacity and partnership-based research with external institutes to support drug development and evidence generation.
Mentorship, business development, internationalisation and investor-preparation services for early-stage health startups.
Design and deployment of patient engagement initiatives to integrate patient perspectives into product development and communication.
Regional commercial offices and local contact points across 40+ countries to support market access, distribution and customer service.
Expertise Areas
- Contract manufacturing (CMO)
- Biologics and vaccine production
- Biosimilars manufacturing
- Pharmaceutical R&D and external collaborations
Key Technologies
- Biologics and vaccine manufacturing
- Biosimilars production
- Sterile injectable fill–finish
- Solid dose manufacturing (tablets, capsules)
News & Updates
Support for startups through Insud Pharma's ChemoStart accelerator
Exeltis, as part of Insud Pharma, supports innovative startups like BioDan, Brainguard, and Insulclock through the ChemoStart accelerator, fostering healthcare innovation and social impact.
Doctor Silvia Gold awarded Gold Medal by the Royal Academy of Medicine and Surgery of Murcia
Silvia Gold, President of the Mundo Sano Foundation, received the highest recognition from the Royal Academy of Medicine and Surgery of Murcia for her dedication to combating Chagas disease.
mAbxience's agreement with AstraZeneca to produce Covid-19 vaccine
mAbxience, part of the Insud Pharma group, entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America, contributing to global efforts to fight the pandemic.
Support for startups through Insud Pharma's ChemoStart accelerator
Exeltis, as part of Insud Pharma, supports innovative startups like BioDan, Brainguard, and Insulclock through the ChemoStart accelerator, fostering healthcare innovation and social impact.
Doctor Silvia Gold awarded Gold Medal by the Royal Academy of Medicine and Surgery of Murcia
Silvia Gold, President of the Mundo Sano Foundation, received the highest recognition from the Royal Academy of Medicine and Surgery of Murcia for her dedication to combating Chagas disease.
mAbxience's agreement with AstraZeneca to produce Covid-19 vaccine
mAbxience, part of the Insud Pharma group, entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America, contributing to global efforts to fight the pandemic.